Donate to Research

Publications

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

Jama Oncology

JAMA Oncol. 2024 Feb 15:e236789. doi: 10.1001/jamaoncol.2023.6789 Peter W Szlosarek 1 2 3, Benjamin C Creelan 4, Thomas Sarkodie 2, Luke Nolan 5, Paul Taylor 6, Olga Olevsky 7, Federica Grosso 8, Diego Cortinovis 9, Meenali Chitnis 10, Amy Roy 11, David Gilligan 12, Hedy Kindler 13, Dionysis Papadatos-Pastos 14, Giovanni ...

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Creaney, J. et al. Genome Med 14, 58 (2022).

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

Fennell, D. et al. BMJ Open 13, e073120 (2023).

Genes, Chromosomes and Cancer

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways. Genes Chromosomes Cancer (2023).

Jama, M. et al. Genes Chromosomes Cancer (2023).

Family Matters: Germline Testing in Thoracic Cancers

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

Singh, A. et al. Oncogene 42, 572-585 (2023).

Accelerating innovations in systemic therapy for pleural mesothelioma

Fennell, D. A. & Bzura, A. Nat Cancer 3, 902-904 (2022).

Immunotherapy approaches for malignant pleural mesothelioma.

Fennell, D. A., Dulloo, S. & Harber, J. Nat Rev Clin Oncol 19, 573-584 (2022).

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

Fennell, D. A. et al. EClinicalMedicine 48, 101432 (2022).

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Zauderer, M. G. et al. Lancet Oncol 23, 758-767 (2022).

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Carbone, M. et al. J Thorac Oncol 17, 873-889 (2022)

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Kindler, H. L. et al.. Lancet Oncol 23, 540-552 (2022).

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial

Fennell, D. A. et al. Lancet Oncol 23, 374-381 (2022).

Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.

Fennell, D. A. & Dulloo, S. J Thorac Oncol 17, 34-37 (2022).

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Fennell, D. A. et al. Lancet Oncol 22, 1530-1540 (2021).

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Aliagas, E. et al. Br J Cancer 125, 1365-1376 (2021).

NE Journal of Medicine

Perspectives on the Treatment of Malignant Pleural Mesothelioma.

Janes, S. M., Alrifai, D. & Fennell, D. A. N Engl J Med 385, 1207-1218 (2021).

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

Harber, J., Kamata, T., Pritchard, C. & Fennell, D. J Immunother Cancer 9 (2021).

CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition

Pinton, G. et al. Front Oncol 11, 678447 (2021).

Precision Therapy for Mesothelioma: Feasibility and New Opportunities

Dulloo, S., Bzura, A. & Fennell, D. A. Cancers (Basel) 13 (2021).

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

Zhang, M. et al. Nat Commun 12, 1751 (2021).

Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment

JCO Precision Oncology

Popat, S. et al. JCO Precis Oncol 5, 39-43 (2021).

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet

Scagliotti, G. V. et al. Lancet Respir Med 7, 569-580 (2019).

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

Springer Link

van Brummelen, E. M. J. et al. Invest New Drugs 38, 457-467 (2020).

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study

Journal of Clinical Oncology

Fennell, D. A. et al. J Clin Oncol 37, 790-798 (2019).

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

BMC

Fennell, D. A. et al. Trials 19, 233 (2018).

BTS guideline for the investigation and management of malignant pleural mesothelioma

BMJ Journals

Woolhouse, I. et al. BMJ Open Respir Res 5, e000266 (2018).

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Nature

PubMed ID: 28445469

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

The Lancet

Maio, M. et al. Lancet Oncol 18, 1261-1273 (2017).

Novel insights into mesothelioma biology and implications for therapy

Nature Reviews Cancer

Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Nat Rev Cancer 17, 475-488 (2017)

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

JAMA Oncology

Szlosarek, P. W. et al. JAMA Oncol 3, 58-66 (2017).

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

The Lancet

Krug, L. M. et al. Lancet Oncol 16, 447-456 (2015).

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation

European Journal of Cancer

Hasan, B. et al. Eur J Cancer 50, 2771-2782 (2014).